Please login to the form below

Not currently logged in
Email:
Password:

Novartis wins European approval for triple blood pressure pill

Rasitrio combines the pharma company's Rasilez/Tekturna (aliskiren) with two generic antihypertensive drugs

Novartis has been granted approval by the European Commission for Rasitrio, a triple combination pill for high blood pressure.

Rasitrio combines Novartis' proprietary renin inhibitor Rasilez/Tekturna (aliskiren) with two generic antihypertensive drugs, the calcium antagonist amlodipine and diuretic hydrochlorothiazide. It was approved in the US as Amturnide a year ago.

It has been approved as substitution therapy for patients with high blood pressure that are adequately controlled by the combination of the three components at the same dose, according to Novartis.

The company notes that up to 85 per cent of blood pressure patients require multiple medications to reach treatment targets, and compliance with therapy is a "major challenge for primary care physicians".

"Simplification of treatment for high blood pressure patients on three or more therapies is key to improving patient compliance and outcomes," commented Professor Josep Redon of the Hospital Clinico, University of Valencia, Spain.

Faced with patent expiration for its top-selling Diovan (valsartan) blood pressure drug - which brought in $4.48bn in the first nine months of the year - Novartis has been turning to Rasilez and its line extensions to help soften the blow of generic competition, which has already started in a number of EU countries, as well as Canada and Brazil.

First launched in 2007, Rasilez sales grew 47 per cent to $305m in the first three quarters of 2011, helped by the introduction of dual combinations with other drugs.

Rasilez HCT (aliskiren and hydrochlorothiazide) reached the market in 2008, and was followed in the US only by a valsartan/aliskiren combination - called Valturna - in 2009. Novartis elected not to pursue development of the latter product in Europe after the EMA asked for additional information. A combination of aliskiren and amlodipine was approved in 2010 in the US as Tekamlo and in the EU as Rasilamlo earlier this year.

"For the first time, high blood pressure patients in Europe with complex needs will have access to a single pill combining the unique properties of Rasilez with two well-established and effective high blood pressure treatments," said David Epstein, division head of Novartis Pharmaceuticals.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics